Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players├óÔéČÔäó financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Migraine Brainstem Aura Companies

Migraine with brainstem aura, previously known as basilar-type migraine, is a subtype of migraine characterized by aura symptoms originating from the brainstem. Aura symptoms can include visual disturbances, vertigo, speech difficulties, and other neurological symptoms. Companies in the healthcare and pharmaceutical industry may be involved in the development of treatments or therapies for migraines, including those associated with brainstem aura.

Migraine with Brainstem Aura Companies

 


Latest Migraine with Brainstem Aura Companies Update:

Biogen acquires Alder BioPharmaceuticals: This move expands Biogen's neurology portfolio and grants them access to Alder's rimegepant oral medication for preventing migraine, which could potentially benefit MBA patients.


Eli Lilly partners with Cohero Health to develop digital therapeutics for migraine: This collaboration aims to leverage Cohero's expertise in behavioral health solutions to create digital tools for managing and preventing migraine attacks, including those with brainstem aura.


Botox receives FDA approval for preventive treatment of chronic migraine: While not specific to MBA, this broader approval for chronic migraine could indirectly benefit some patients who experience migraine with brainstem aura as part of their chronic migraine condition


List of Migraine with Brainstem Aura Key companies in the market

  • Allergen Plc,

  • Merck & Co., Inc.,

  • Pfizer, Inc.,

  • GlaxoSmithKline Plc,

  • Abbott Laboratories,

  • AstraZeneca,

  • Eisai Co., Ltd.,

  • Endo International Plc,

  • Impax Laboratories,

  • Eli Lily and Company,

  • Johnson & Johnson


Migraine with Brainstem Aura Market Scenario


Migraine with brainstem aura market is expected to grow USD 10.67 Billion at a CAGR 5.30% the forecast period 2023 to 2030. A migraine with brainstem aura is also known as a basilar migraine or basilar artery migraine. It is a rare type of a migraine that begins in the base of the brain (brain stem). A migraine with brainstem aura occurs in about 1.5% of the patients suffering from with a headache. This migraine can occur in men and women of all ages.


The symptoms of this migraine include visual disturbances in both eyes, vertigo, hearing problems, nausea, dizziness among others. A migraine with brainstem aura (MBA) may affect one or both the sides of the brain. This rare migraine may be caused by a constriction of blood vessels that limit the blood flow to the brain. Moreover, certain external factors such as stress, motion sickness, epilepsy, alcoholism, prolonged hunger, excessive use of headache medications can trigger basilar artery migraines.


The factors such as rising prevalence of a migraine and growing awareness about rare types of migraines in the developed economies are major drivers for the market growth. In addition, the rising need for better treatment approaches, increasing investment of biotechnology and pharmaceutical industries in research & development (R&D) are expected to contribute to the growth of the market. However, side effects associated with migraine treatment drugs may hamper the growth of the market during the forecast period.


Segmentation


The migraine with brainstem aura market has been segmented into diagnosis, treatment, distribution channel, and end-user.


The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), computerized tomography (CT), and others.


The market, on the basis of treatment, has been segmented into abortive medication and preventive medication. The abortive medication segment has been segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-nausea medications, and others. The preventive medication segment has been further segmented into botox injections, antidepressants, and others.


On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, and others.


The market, by end-user, has been segmented into hospital & clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The migraine with brainstem aura market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European migraine with brainstem aura market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The migraine with brainstem aura market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The migraine with brainstem aura market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global market.


Regional Market Summary


Migraine with Brainstem Aura Market Share (%), by Region, 2017


Migraine with Brainstem Aura Market Share


Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the migraine with brainstem aura market owing to a well-developed healthcare sector, rising prevalence of migraine and growing healthcare expenditure. According to the Centers for Disease Control and Prevention (CDC), in 2015, 20% of women and 9.7% of men aged 18 or more had a migraine. Additionally, the large number of research and development (R&D) activities contributes to the growth of the market.


Europe is expected to hold the second largest position in the migraine with brainstem aura. The market growth in this region is attributed to the availability of funds for research, growing prevalence of migraine, and increasing healthcare expenditure. According to the World Health Organization (WHO), it is estimated that around 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK.


The migraine with brainstem aura market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of migraine and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.


Migraine with Brainstem Aura Market, by Diagnosis



  • Magnetic Resonance Imaging (MRI)

  • Computerized Tomography (CT)

  • Others


Migraine with Brainstem Aura Market, by Treatment



  • Abortive Medication


    • Non-steroidal anti-inflammatory drugs (NSAIDS)

    • Ibuprofen

    • Others

    • Anti-nausea Medications




  • Preventive Medication


    • Botox Injections

    • Antidepressants

    • Others



Migraine with Brainstem Aura Market, by Distribution Channel



  • Retail Pharmacies

  • Hospital Pharmacies

  • Others


Migraine with Brainstem Aura Market, by End-User



  • Hospital & Clinics

  • Diagnostic Centers

  • Others


Migraine with Brainstem Aura Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.